Pharmaceutical Services M&A Transactions

Alfasigma strengthens its European specialty care operations by acquiring Nordic Pharma from SEVER Life Sciences, enhancing its market reach and therapeutic focus.

Resonant Clinical Solutions acquires Creapharm Bioservices, enhancing its specialized capabilities for advanced therapies and cryogenic storage in Europe.

Vertex Pharmaceuticals completes $10 billion acquisition of Crinetics Pharmaceuticals, bolstering its presence in rare endocrine diseases with new therapeutic assets.

CVC Capital Partners Fund IX and GBL launch a €10.7 billion takeover bid for Recordati, backed by substantial equity, debt financing, and PIK notes.

Samsung Biologics moves to acquire PolyPeptide Group for approximately $1.6 billion, expanding its CDMO services into peptide manufacturing.

CVC Capital Partners and GBL launch a €10.7 billion take-private offer for Recordati. HIG Capital's Medisolve acquires WISAG MS. Other Italian PE deals detailed.

Warburg Pincus exits Certified Group, a $300M revenue lab testing platform, to Mérieux NutriSciences in a strategic acquisition.

Linden Capital Partners has acquired ArtesRx, a rapidly expanding specialty pharmacy, from Flexpoint Ford. Learn more about this strategic healthcare deal.

Agentis Health Group strengthens its digital health capabilities by acquiring Clinical Pharmacist Solutions, focusing on integrated long-term condition management.

Grupo Elfa

Patria Investimentos evaluates Grupo Elfa's portfolio for divestitures, aiming to reduce debt and enhance focus on high-margin healthcare segments like oncology.

Tempus AI strengthens its AI oncology platform by acquiring Personalis for $1.5 billion, boosting its capabilities in molecular residual disease detection.

Pinnaql strengthens its life sciences consulting platform by acquiring Pharma Resource Group, boosting scientific and manufacturing advisory capabilities.

Fulcrum Therapeutics

Fulcrum Therapeutics and Slate Medicines merge, creating a new Nasdaq-listed biotech focused on migraine treatments, bolstered by $245 million in new funding.

LEO Pharma secures global rights to dersimelagon, a promising oral therapy for rare skin conditions EPP and XLP, in a deal valued up to $435 million.